Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11114MR)

This product GTTS-WQ11114MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Hodgkin's disease (HD), Anaplastic large cell lymphoma (ALCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11114MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10340MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ2963MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ14325MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ3028MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ6402MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ12968MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ9014MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ4611MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW